Akari Therapeutics, Plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AKTX | ATORX.ST | HBP.TO | ALLR | DTC.CN | ATNM | |
|---|---|---|---|---|---|---|
| Market cap | 21.23M | 38.18M | 70.27M | 17.18M | 25.50M | 44.33M |
| P/E (TTM) | — | — | — | — | — | 3.9 |
| Forward P/E | -1.1 | -0.1 | -8.4 | -1.3 | — | -2.7 |
| Price/book | 0.9 | 0.3 | 4.8 | 4.9 | 7.3 | 1.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −62.30% | −99.44% | −54.68% | −2.70% | −61.05% | +6.82% |
| Today | +13.98% | 0.00% | 0.00% | −4.42% | −1.47% | +0.71% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All AKTX news ›Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value Importantly for Akari, Mr. Vat-Ho brings…
Akari Therapeutics grants executive stock options
Edible Garden Announces Commercial Supply Agreement and Strategic Partnership with Caney Fork Farms Hyperliquid Strategies Inc Announces Increase of Stock Repurchase Program to $100 Million AI OKTO Corp. Declares Special Dividend of $3.50…
Akari Therapeutics Plc Initial Statement of Beneficial Ownership
Edible Garden Announces Commercial Supply Agreement and Strategic Partnership with Caney Fork Farms MISSION SUCCESS: Rocket Lab Launches 98th Electron Mission Axon Announces Body 5: Next-Generation Camera Built for the AI Era Parabilis…
Akari Therapeutics' Patel exercises pre-funded warrants
Akari Therapeutics (AKTX) is an oncology biotech developing PH1-based antibody–drug conjugates targeting Trop2 and other solid tumor antigens using a spliceosome-modulating payload. - [Form 4] Akari Therapeutics Plc Insider Trading…
Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today issued the following letter to…
Akari Therapeutics grants director conditional stock awards
Director receives conditional stock grants for unpaid retainers at Akari Therapeutics (AKTX). Stock Titan - [Form 4] Akari Therapeutics Plc Insider Trading Activity Akari Therapeutics grants director conditional stock awards The grants are…
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
Akari is exploring potential payload licensing and dual-payload approaches based on PH1 alongside development of AKTX-101. Akari Therapeutics (AKTX) outlined its AKTX-101 development priorities in a new CEO Corner, targeting Phase 1…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net10
- biospace.com1
- globenewswire.com1
- natlawreview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.